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Abstract
The role of the cellular protein LRP6 in anthrax toxin entry is controversial. Previous studies showed that LRP6 was important
for efficient intoxication of human M2182 prostate carcinoma cells but other studies performed with cells from gene-
knockout mice demonstrated no role for either LRP6 or the related LRP5 protein in anthrax toxin entry. One possible
explanation for this discrepancy is that LRP6 may be important for anthrax toxin entry into human, but not mouse, cells. To
test this idea we have investigated the effect of knocking down LRP6 or LRP5 expression with siRNAs in human HeLa cells.
We show here that efficient knockdown of either LRP6, LRP5, or both proteins has no influence on the kinetics of anthrax
lethal toxin entry or MEK1 substrate cleavage in these cells. These data argue against a human-specific role for LRP6 in
anthrax toxin entry and suggest instead that involvement of this protein may be restricted to certain cell types
independently of their species of origin.
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Introduction
Bacillus anthracis, the etiological agent of anthrax, secretes a
tripartite toxin, which is one of two major virulence factors.
Anthrax toxin is composed of the receptor binding moiety,
protective antigen (PA), and two catalytic moieties: Lethal factor
(LF), a zinc –dependent metalloprotease that cleaves MAP kinase
kinases (MAPKKs), [1–3] and edema factor (EF), a calcium- and
calmodulin-dependent adenylate cyclase that raises cAMP levels
[4]. LF and EF combine with PA to form lethal toxin (LeTx) and
edema toxin (EdTx), respectively. Both 83 kD and 63 kD forms of
PA (PA83 and PA63) can bind to either of two cellular receptors,
ANTXR1 (anthrax toxin receptor 1/tumor endothelial marker 8;
ATR/TEM8) or ANTXR2 (anthrax toxin receptor 2/capillary
morphogenesis factor 2;CMG2) [5,6]. Receptor-bound PA83 is
cleaved by cell-surface furin into the 63 kD form [7]. PA63 forms a
heptameric ring structure [PA63(7)], termed a prepore, at neutral
pH [8]. EF and LF bind the prepore and the toxin/receptor
complex is endocytosed primarily via clathrin-mediated endocy-
tosis [9] and trafficked to an endocytic compartment where low-
pH triggers PA63(7) pore formation and translocation of EF and LF
into the cytosol [10–12].
Currently there is a controversy about the role played in
anthrax toxin entry by the low-density lipoprotein receptor-related
protein LRP6, which interacts with both ANTXR1 and ANTXR2
[13]. Evidence in favor of a specific role was provided by Cohen
and colleagues [13]. In that study, LRP6 was identified through a
genome-wide antisense RNA screening approach to be important
for intoxication of human M2182 prostate carcinoma cells by PA
and FP59, a recombinant toxin comprised of the N-terminal
portion of LF fused to Pseudomonas exotoxin A. Consistently,
siRNA-mediated knockdown of LRP6 levels in these cells reduced
their toxin sensitivity by several orders of magnitude, an effect that
was partially overcome by expression of an siRNA-resistant form
of LRP6. LRP6 deficiency in M2182 cells was also associated with
reduced levels of PA binding and pore formation, and expression
of a dominant-negative form of LRP6, lacking its cytoplasmic
domain, rendered these cells resistant to intoxication. This group
also showed that LRP6 could be co-precipitated with both
ANTXR1 and ANTXR2. Furthermore, they showed that
siRNA-mediated knockdown of LRP6 rendered RAW264.7
mouse macrophages resistant to intoxication by PA and LF,
although this effect was much more modest (,3-fold) than that
seen with M2182 cells. LRP6-specific antibodies also protected
RAW264.7 cells from intoxication.
By contrast, Duesbury and colleagues found that LRP6
+/2 and
LRP5
2/2 mice were just as susceptible to killing after LeTx
injection as wild-type mice [14]. LRP5 is a protein that is highly
related to LRP6 [15]. In addition, they showed that mouse embryo
fibroblasts (MEFs) that were isolated from LRP6
2/2 or LRP5
2/2
mice were just as susceptible to intoxication by PA and FP59, and
to MEK1 cleavage by LF and PA, as those isolated from wild-type
mice [14]. They went on to show that there is no obvious receptor-
specific role for LRP6 since knocking down this protein had no
effect on the toxin sensitivity of PA receptor-deficient Chinese
hamster ovary cells that were engineered to express either
ANTXR1 or ANTXR2.
Duesbury and colleagues put forward several possible explana-
tions for the discrepant results. Since their data argue against an
anthrax toxin receptor-specific role for LRP6, and there is no
evidence for functional redundancy between LRP6 and LRP5 in
toxin entry, they suggested that instead LRP6 might function in
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we show that siRNA-mediated knockdown of LRP6 and/or LRP5
levels has no impact on the kinetics of anthrax toxin entry into
human HeLa cells. These data argue against a human-specific
role for either LRP6 or LRP5 in anthrax toxin entry and suggest
that the requirement for LRP6 might be restricted to certain cell
types.
Results and Discussion
Efficient siRNA-mediated knockdown of LRP6 and LRP5
expression in HeLa cells
HeLa cells were chosen as a model human cell type because
they have been used extensively for anthrax toxin entry studies and
they are efficiently transfected with siRNAs [9,16,17]. To
Figure 1. siRNA knockdown of LRP5 and LPR6 mRNA and protein expression in HeLa cells. A) RT-PCR analysis of LRP5 and LRP6 levels in
HeLa cells transfected either with cognate pools of siRNAs or with siRNAs directed against luciferase (negative control). These experiments were each
performed with triplicate samples and the mean average results are shown along with the standard deviation of the data indicated by error bars. B)
Immunoblot analysis of LRP5 and LRP6 protein levels in cells transfected with the pools of siRNAs described in panel A. To control for equivalent
cellular protein levels imunoblot analysis was also conducted on tubulin. C) The relative levels of LRP5 and LRP6 proteins in each sample shown in
panel B were quantitated relative to the levels of tubulin in each sample using the fluorescence-scanning method described in materials and
methods.
doi:10.1371/journal.pone.0001817.g001
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expression, these cells were transfected with cognate siRNAs.
These studies revealed an approximately 20-fold decrease in LRP5
and a 10-fold decrease in LRP6 mRNA transcripts in the
transfected HeLa cells, relative to the levels observed with cells
transfected with a negative control siRNA directed against
luciferase (Fig. 1A). Consistently, siRNA transfection significantly
reduced LRP5 and LRP6 proteins levels, as judged by immuno-
blotting (Fig. 1B and 1C). Importantly, LRP6 protein was reduced
to undetectable levels in HeLa cells transfected with the
corresponding siRNAs (Fig. 1B and C). Taken together these
studies show that expression of LRP5 and LRP6 can be markedly
reduced in siRNA-transfected HeLa cells. In addition, the level of
siRNA-mediated knock-down of LRP5 and LRP6 exceeded those
achieved in previous studies concerning the role of LRP5 and
LRP6 in anthrax toxin internalization.
LRP6 and LRP5 are not important for intoxication of HeLa
cells
To test the importance of LRP6 and/or LRP5 for anthrax toxin
entry, HeLa cells transfected with different siRNAs were tested for
their susceptibility to intoxication in the presence of varied
amounts of PA83 and a fixed amount of LFN-DTA. LFN-DTA is a
hybrid toxin consisting of the PA-binding subunit of LF fused to
the catalytic domain of diphtheria toxin A chain [18]. This
recombinant toxin uses precisely the same PA-dependent pathway
for cellular entry as that used by wild-type LF, and indeed it has
been used as a convenient tool to study the anthrax toxin entry
mechanism because, unlike wild-type LF, it can cause cell death in
many cell types following its translocation into the cytosol [19–21].
For positive control purposes, HeLa cells were also transfected
with siRNAs directed against both ANTXR1 and ANTXR2,
which results in complete protection of the cells from intoxication
because of efficient receptor knockdown (Fig. 2).
These studies revealed that the cells transfected with LRP5-
and/or LRP6-directed siRNAs were just as susceptible to
intoxication as were untransfected cells or cells transfected with
a control firefly luciferase-specific siRNA (Fig. 2). These data argue
against a specific requirement for either LRP6 or LRP5 in anthrax
toxin entry.
LRP6 and LRP5 do not influence the kinetics of PA63(7)
pore formation in HeLa cells.
The toxin sensitivity studies shown in Fig. 2 are conducted over
a two day time frame and, as such, they do not provide any
information on the kinetics of toxin entry which is usually
complete within a 60- to 90-minute time period [2,22,23]. To
explore the possibility that LRP6 and/or LRP5 might influence
the kinetics of toxin entry we first evaluated the rate of PA63(7)
pore formation in siRNA-transfected HeLa cells. Pore formation
was evaluated during the first 35 minutes after initiating toxin
internalization, using a standard approach, namely by the acid-
pH-dependent conversion of PA63(7) to an SDS-resistant oligo-
meric species [8,11,24]. These studies revealed that the kinetics of
pore formation in cells transfected with LRP5 and/or LRP6
siRNAs were precisely the same as those seen in cells transfected
with the control luciferase siRNA (Fig. 3A and 3B). As expected,
HeLa cells treated with siRNAs targeting ANTXR1 and
ANTXR2 showed little quantifiable pore formation (Fig. 3A and
3B). Taken together these studies demonstrate no obvious effect of
knocking down LRP5 and/or LRP6 expression on the early
kinetics of toxin uptake and acid pH-dependent PA pore
formation.
LRP6 and LRP5 do not influence the kinetics of MEK1
substrate cleavage in HeLa cells
To confirm that LRP6 and LRP5 play no role in anthrax toxin
entry into HeLa cells, we monitored the effect of knocking down
expression of these proteins upon the kinetics of MEK1 cleavage
by LF. LF cleavage removes the eight N-terminal amino acids of
MEK1, an event that can be scored by immunoblotting using an
antibody specific for the N-terminal region of MEK1 [1–3,23].
MEK1 cleavage was monitored by immunoblotting at 0, 30, 45,
60, 75 and 90 minutes after LeTx addition and the signal obtained
in each case was compared to that of Ku86, a cellular protein that
is not a LF substrate. These studies revealed that siRNA-mediated
knockdown of LRP6 or LRP5 levels had no influence on the
MEK1 cleavage kinetics in HeLa cells (Compare these samples to
the control samples transfected with luciferase siRNA: Fig. 4A and
4B). As expected, HeLa cells transfected with siRNAs targeting
ANTXR1 and ANTXR2 were completely resistant to LF-
mediated MEK1 cleavage (Fig. 4A and 4B).
In summary, the data obtained in this report argue against a
human specific role for LRP6 or for the related LRP5 protein in
anthrax intoxication. Efficient siRNA-mediated knockdown of
expression of either or both LRP5 and LRP6 in HeLa cells had no
impact on the kinetics of anthrax toxin uptake or pore formation
in acidic endosomes. Furthermore, these treatments did not alter
the kinetics of MEK1 cleavage following LeTx uptake into HeLa
cells. These data lead us to conclude that LRP6 may be important
for anthrax toxin uptake in different cell types independently of
their species of origin, as was suggested by Duesbury and
colleagues [14]. However, future studies in this area will be
required to clarify the precise context(s) under which anthrax toxin
entry is dependent upon LRP6.
Materials and Methods
siRNA transfections
HeLa cells were reverse-transfected using RNAiMax (Invitrogen)
according to manufacturer’s instructions with 32 nM siRNA. siRNAs
were obtained from Dharmacon: LRP6 On-Target Plus SmartPool
siRNA (GCAGAUAUCAGACGAAUUUUU, CAGAUGAACUG
GAUUGUUAUU, CCACAGAGCGAUCACAUUAUU, GCUCA
ACCGUGAAGUUAUAUU) LRP5 On-Target Plus Smartpool
Figure 2. Reduced levels of LRP6 and/or LRP5 do not influence
the toxin sensitivity of HeLa cells. siRNA-transfected cells were
incubated with varying amounts of PA83 (as shown) and with 5610
210
ML F NDTA. These experiments were performed with triplicate samples
and the results shown are the mean average values with the standard
deviation of the data indicated with error bars.
doi:10.1371/journal.pone.0001817.g002
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PLoS ONE | www.plosone.org 3 March 2008 | Volume 3 | Issue 3 | e1817Figure 3. Reduced levels of LRP6 and/or LRP5 do not influence the kinetics of PA63(7) pore formation in HeLa cells. A) The kinetics of
PA pore formation in siRNA-transfected HeLa cells was evaluated as described in materials and methods. The cells were lysed at different time points
after initiating toxin entry (0, 15, 25, 35 mins) and the protein lysates subjected to SDS-PAGE and immunoblotting with anti-PA antibody to detect the
SDS-resistant oligomeric PA63(7) pore species. (B) Quantitation of the levels of SDS-resistant pore species in the different time point samples shown in
panel A. As described in materials and methods, the relative levels shown were determined by comparing the pore:tubulin ratio in each sample. The
experiment shown is representative of three independent experiments.
doi:10.1371/journal.pone.0001817.g003
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PLoS ONE | www.plosone.org 4 March 2008 | Volume 3 | Issue 3 | e1817Figure 4. Reduced levels of LRP6 and/or LRP5 do not influence the kinetics of MEK1 cleavage in HeLa cells. A) HeLa cells transfected
with different siRNAs were incubated with LeTx. Protein lysates were prepared at different time points and subjected to SDS-PAGE and
immunoblotting with an anti-N-terminal MEK-1 antibody. Ku86, which is not an LF substrate, was also immunblotted as a loading control. B) The
relative signal obtained with the N-terminal MEK1 antibody was compared with that associated with Ku86 in each sample shown in panel A. The
experiment shown is representative of three independent experiments.
doi:10.1371/journal.pone.0001817.g004
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GUGUCUAUUU, GGACGGACCUACGGAGGAUUU, GUAC
AGGCCCUACAUCAUUUUU), ANTXR1 On Target SmartPool
siRNA (CCAGUGAGCAGAUUUAUUAUU, GCUAAUAGGU-
CUCGAGAUCUU, GAAGAAGUCCUGCAUCGAAUU, GGAA-
CAACCUUAAUGAAACUU) ANTXR2 On Target SmartPool
siRNA (Dharmacon GUAAAGGCUUGGAGGAUUUU, GCUA
GCGAAUGAACAAAUUUU, GGGCUAGUGUUUAUUGUGU
UU, UAUACUAGCUCAGUCAUGUUU) and GL2 firefly lucifer-
ase siRNA (target DNA sequence: CGTACGCGGAATACT TCGA)
LRP5 and LRP6 protein expression analysis
Approximately 5610
4 HeLa cells plated in individual wells of a
12-well plate were reverse-transfected with different siRNA pools
targeting LRP5, LRP6, both LRP5 and LRP6, or firefly luciferase
(negative control). After 48 hours, cells were lysed with reducing
gel sample buffer containing 2% SDS and 100 mM DTT [24].
Lysate samples were separated by denaturing SDS-PAGE and
transferred to PVDF membranes (Millipore). These membranes
were blocked and incubated with antibodies in TBS-T containing
5% milk: The same conditions were used for all immunoblotting
experiments described in this report. The antibodies used were the
LRP5-specific (Rabbit anti-LRP5, Zymed) diluted 1:200 and the
LRP6-specific (LRP6 C5C7), Cell Signaling Technologies) diluted
1:1000. Tubulin was detected as a loading control (a/b-Tubulin
antibody, Cell Signaling Technologies) diluted 1:1000. The Alexa
Fluor 680-conjugated secondary antibody used in each case was
the goat anti-rabbit IgG (Alexa Flour 680 goat anti-rabbit IgG,
Invitrogen) diluted 1:20,000. The samples were then scanned and
analyzed with the fluorescence-scanning Odyssey system and its
associated software (Li-Cor).
RT-PCR analysis of LRP5 and LRP6 mRNA expression
Approximately 1610
5 HeLa cells plated in individual wells of a
6-well plate were reverse-transfected with the different siRNA
pools described above. RNA was harvested using the Qiagen
RNeasy kit at 48 hours post siRNA transfection for RT-PCR
analysis: The cDNA synthesis was performed with the SuperScript
III reverse transcriptase system (Invitrogen) using 2 mg of total
RNA from each sample and random hexamers as primers. PCR
amplification was subsequently performed for 40 cycles (95uC for
15 seconds, 60uC for 1 minute) with an ABI Prism 7900HT
instrument and with primers obtained from the validated library of
Qiagen Quantitect primers along with Sybr green PCR master
mix (Applied Biosystems). The relative levels of LRP5 or LRP6
mRNA transcripts were then determined using the Comparative
Ct (DDCt) method using GAPDH (CCTCTGACTTCAACAGC-
GACAC, TTCCTCTTGTGCTCTTGCTGG) as an endoge-
nous mRNA control.
Cell intoxication assays
Triplicate samples of approximately 5610
3 HeLa cells seeded in
individual wells of a 96-well plate were reverse-transfected with the
different siRNAs. After 48 hours, cells were incubated with
5610
210ML F N-DTA and with varying concentrations of PA
for 48 hours [18]. Cell viability was then assayed with the Cell
Titer-Glo assay (Promega) as previously described [24].
SDS-resistant pore formation
Formation of the SDS-resistant PA63(7) pore species was
detected by immunoblotting as previously described [24], except
cells were incubated with 2.5610
28M PA and 2610
29M LF for
2 hours at 4uC, washed and shifted to 37uC for the indicated
times. Cells were lysed with reducing gel sample buffer, protein
lysates were subjected to SDS-PAGE and SDS-resistant pore was
detected with anti-PA (Goat anti-PA, List Labs) diluted 1:2,000.
The secondary antibody used in this case was the Alexa Fluor-680
conjugated rabbit anti-goat (Invitrogen) diluted 1:20,000. The
immunoblotting conditions were the same as described above and
western blot scanning and analysis was conducted using the
Odyssey system and its associated software (LiCor).
MEK1 Cleavage assays
MEK1 cleavage was detected by immunoblotting as previously
described [24], except that samples were collected directly with
reducing gel sample buffer. Membrane blocking and antibody
dilutions were performed with TBS-T containing 5% milk as
described above. The N-terminal MEK1 antibody (Anti-MEK1
N-terminal) was obtained from Calbiochem (used at 1:1,000) and
the Ku86 antibody (Ku-86 B-1) was obtained from Santa Cruz
Biotechnology (used at 1:500 dilution). Alexa Fluor-680 conjugat-
ed anti-Rabbit IgG and Alexa Fluor-680 conjugated anti-mouse
IgG (Invitrogen) were used as secondary antibodies (both diluted
1:20,000). Western blot scanning and analysis was conducted using
the Odyssey system and its associated software (LiCor).
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